Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel, achieved significant initial results. "We believe the initial results from our "Get Phexxi" marketing campaign demonstrate that we are achieving our goals for this campaign: to raise awareness of this important birth control option and to drive women to healthcare practices for Phexxi," said Evofem Biosciences' CEO, Saundra Pelletier.

Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact

Blue Apron

Clearway Energy

Humana

Pool

Wendy's

Walmart

Insiders sell for many reasons, but they only buy for one. To make money.

7 Stocks for Sale That Have Insider Buying

SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection.

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention

The stock price of Evofem Biosciences Inc (NASDAQ: EVFM) increased by 18.94%. This is why it happened.

EVFM Stock Price Increased 18.94%: Why It Happened

Evofem recently launched the first new non-hormonal birth control option in decades. Clinical efficacy falls short of the copper IUD, PARAGARD, but that device I believe may come with significant side effects.

Evofem Biosciences Launches Phexxi: Will Peak Sales Surprise?

The company's performance during the fourth quarter was short of expectations.

Why Evofem Biosciences Stock Is Falling Today

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q4 2020 Results - Earnings Call Transcript

Shares of Evofem Biosciences (NASDAQ:EVFM) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 85.19% over the past year to ($0.50), which missed the estimate of ($0.36).

Evofem Biosciences: Q4 Earnings Insights

SAN DIEGO, March 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2020. "2020 was a year of execution for Evofem, marked by the...

Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Borr Drilling Ltd

iBio

Safe Bulkers

Timber Pharmaceuticals

These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first on InvestorPlace.

7 Penny Stocks In a Make-or-Break Year

SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and year ended December 31, 2020 as follows: Date Thursday, March 4, 2021 Time...

Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021

Initial prescription data for Phexxi looks very positive. Both the number of new users and estimated revenues to date have exceeded my initial modeling.

Evofem: Initial Sales Are Highly Encouraging

SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi®...

Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021

SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period...

The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020. In advance of the virtual conference and...

Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

EVFM has dipped back into the low $2s due to the daunting task of launching a product without a major company's assistance. I review recent developments and then run my estimates of revenue ramp vs. cash burn to establish a valuation for the stock.

Evofem: The Race Between Revenue Ramp And Cash Burn

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2020 Results - Earnings Call Transcript

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2020 Results - Quick Version Earnings Call Transcript

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2020. "We are excited by the early momentum of our commercial launch of Phexxi, the...

Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Evofem vaginal pH modulation technology is a differentiated product being used to target unmet needs in women's health.

Evofem's Major Sell-Off Undervalues The Company's Long-Term Potential

SAN DIEGO, Oct. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. "We are...

Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Evofem Biosciences (EVFM) Stock?

Evofem: Why I Bought Friday's Massive Spike Down

The company's CEO made a noteworthy move.

News for Evofem Biosciences Inc Stock (EVFM)